• Altimmune will present RECLAIM Phase 2 pemvidutide results for alcohol use disorder at AASLD’s The Liver Meeting on Nov. 9, 2026.
• Topline results announced in July showed reduced heavy drinking versus placebo, met key secondary goals and indicated generally favorable tolerability.
• An FDA meeting scheduled for December will address the Phase 3 registration program for pemvidutide in alcohol use disorder.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Altimmune Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202611051000PRIMZONEFULLFEED9870534) on November 05, 2026, and is solely responsible for the information contained therein.